Market Overview

Leerink Swann Upgrades MedAssets To Outperform

Related MDAS
MedAssets 13D Filing Shows Holder Starboard Has 8.7% Stake, Delivers Letter To Board
Benzinga's Top Downgrades
IPC Healthcare, (IPCM) in Focus: Stock Moves 5.4% Higher - Tale of the Tape (Zacks)

Analysts at Leerink Swann upgraded MedAssets (NASDAQ: MDAS) from Market Perform to Outperform.

The target price for MedAssets is set to $26.

MedAssets shares have fallen 6.51% over the past 52 weeks, while the S&P 500 index has gained 19.79% in the same period.

MedAssets' shares rose 0.28% to close at $21.25 yesterday.

Latest Ratings for MDAS

Jul 2015KeyBancDowngradesOverweight
Jul 2015Cowen & CompanyDowngradesOutperformMarket Perform
Jul 2015Evercore PartnersDowngradesBuyHold

View More Analyst Ratings for MDAS
View the Latest Analyst Ratings

Posted-In: Leerink SwannUpgrades Analyst Ratings


Related Articles (MDAS)

Get Benzinga's Newsletters